Vor Biopharma, Inc. (VOR)

NASDAQ: VOR · IEX Real-Time Price · USD
4.93
-0.18 (-3.52%)
At close: Aug 19, 2022 4:00 PM
5.16
+0.23 (4.67%)
After-hours: Aug 19, 2022 6:20 PM EDT
-3.52%
Market Cap 187.62M
Revenue (ttm) n/a
Net Income (ttm) -81.20M
Shares Out 38.06M
EPS (ttm) -2.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 81,878
Open 5.00
Previous Close 5.11
Day's Range 4.88 - 5.23
52-Week Range 3.83 - 18.52
Beta n/a
Analysts Buy
Price Target 21.55 (+337.1%)
Earnings Date Aug 8, 2022

About VOR

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaborat... [Read more...]

Industry Biotechnology
IPO Date Feb 5, 2021
Employees 135
Stock Exchange NASDAQ
Ticker Symbol VOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for VOR stock is "Buy." The 12-month stock price forecast is 21.55, which is an increase of 337.12% from the latest price.

Price Target
$21.55
(337.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%

The consensus price target hints at a 295% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es...

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30...

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming invest...

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Pre...

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for treatment of acute myeloid leukemia

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31...

Vor to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be p...

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPCs) enabling new therapeutic approaches following tra...

Vor Bio Announces Retirement of Chief Medical Officer

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for V...

Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

BOCA RATON, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #Biomanufacturing--Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases.

Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full yea...

Vor to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be ...

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Exec...

Vor to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Exec...

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor's President and Chief Exec...

Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 186.2% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the po...

Vor Reports Third Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended S...

Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel cell th...

Vor to Present New Platform and Preclinical Data at ASH

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the upcoming presentation of new data from its nove...

Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

Data covering preclinical proof of concept, manufacturing scale-up, and an in-depth genomic survey of VOR33 for potential off-target editing to be presented at the European Society of Gene and Cell Ther...

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's ...

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to VOR33.

Other symbols: PRTC

Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US

The FDA has granted Fast Track designation to Vor Biopharma's (NASDAQ: VOR) VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML). VOR33 consists o...

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended J...

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem C...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Announces Collaboration with Janssen to Develop eHSC Transplants Combined with a Bi-Specific Antibody Therapy for AML

Other symbols: PRTC

Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combination o...